Positive.

From Investing.com: 2025-01-12 03:30:00

Bernstein analysts are bullish on the European pharmaceutical sector heading into 2025, citing solid growth prospects like an 8% EPS CAGR from 2025 to 2030. They believe the sector’s innovative solutions for unmet medical needs will drive long-term growth. The sector’s undervaluation presents a potential re-rating opportunity, with strong cash generation and defensive traits making it attractive in uncertain times. Key factors like stable U.S. drug pricing and improved pipeline execution could further boost the sector’s outlook.



Read more at Investing.com: 3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025 By Investing.com